Kala Bio, Inc. filed an 8-K on November 3, 2026, disclosing the final voting results from its Annual Meeting of Stockholders, at which five proposals were considered and approved by shareholders.

Key Highlights

  • Shares present: A total of 14,459,767 shares of common stock were present in person or represented by proxy at the Annual Meeting.
  • Directors elected: Yonatan Colman and Brendan Purdy were elected as Class III directors to serve until the 2029 Annual Meeting of Stockholders.
  • Executive compensation advisory vote: Named executive officer compensation received 13,474,419 votes in favor on a nonbinding advisory basis.
  • Auditor ratified: Stockholders ratified the selection of HTL International, LLC as independent registered public accounting firm for fiscal year ended December 31, 2026.
  • Reverse stock split approved: Stockholders approved an amendment to the Restated Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-300, at the Board of Directors' sole discretion.
  • Adjournment proposal passed but not used: The adjournment proposal received sufficient votes to be approved, but no motion to adjourn was made as it was determined not to be necessary or appropriate.

Kala Bio Annual Meeting Voting Results: Five Proposals Decided

According to the filing, Kala Bio, Inc. (NASDAQ:KALA) reported final voting results from its Annual Meeting of Stockholders in an 8-K dated November 3, 2026. A total of 14,459,767 shares were present or represented by proxy. The company disclosed that all five proposals put before stockholders were approved.

For Proposal No. 1, stockholders elected Yonatan Colman and Brendan Purdy as Class III directors. Colman received 13,485,088 votes for and 138,862 withheld, while Purdy received 13,486,814 votes for and 137,136 withheld, with 835,817 broker non-votes recorded for each. Proposal No. 2, the nonbinding advisory vote on executive compensation, received 13,474,419 votes in favor, 149,007 against, and 524 abstentions, with 835,817 broker non-votes. Proposal No. 3 ratified HTL International, LLC as auditor for fiscal year 2026, with 14,311,875 votes for, 146,760 against, and 1,132 abstentions.

Proposal No. 4 authorized an amendment to the Restated Certificate of Incorporation to permit a reverse stock split of the common stock at a ratio of not less than 1-for-2 and not greater than 1-for-300, with the timing and specific ratio to be determined by the Board of Directors in its sole discretion. This proposal received 14,064,372 votes for, 287,744 against, and 107,651 abstentions. Proposal No. 5, the adjournment proposal, received 14,041,517 votes for, 303,859 against, and 114,391 abstentions. The filing noted that although the adjournment proposal passed, no motion to adjourn was made because adjournment was determined not to be necessary or appropriate. The filing states these are final voting results and that no other matters were considered or voted upon.

What Was Disclosed

Kala Bio reported final stockholder vote results from its 2026 Annual Meeting, covering director elections, an advisory compensation vote, auditor ratification, approval of a potential reverse stock split, and an adjournment proposal. All five proposals received majority approval.